Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISE in newly diagnosed MAC lung infection
NL-OMON51951Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amikacin liposome inhalation suspension in Mycobacterium avium lung disease and nontuberculous mycobacterial lung disease (2 arms), sponsored by Insmed Incorporated. Primary endpoints: Cross-sectional psychometric validation at baseline, Test-retest reliability and 1 more. Started Aug 2022; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium avium lung diseasenontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NL-OMON51951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51951.